Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.
In a double blind randomized crossover trial lasting 6 months selegiline, a selective MAO-B inhibitor, was tested against placebo for activity on verbal memory performances in Alzheimer-type dementia (DAT). Verbal memory was assessed with the Rey-Auditory-Verbal Learning Test at the start of treatment, at the time scheduled for crossover (90 days) and at the end of the trial (180 days). The results suggest that selegiline possesses significant activity on some memory parameters, which seems to depend on an improvement both in information processing abilities and in learning strategies at the moment of acquisition.
Finali
G
G
Clinica Neurologica, Università di Perugia.
Piccirilli
M
M
Oliani
C
C
Piccinin
G L
GL
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D003071:Cognition / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D012642:Selegiline / Q000627:therapeutic use*; D014706:Verbal Learning / Q000187:drug effects
D012642:Selegiline